Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

VYNE Therapeutics (VYNE) Debt to Equity (2019 - 2021)

VYNE Therapeutics' Debt to Equity history spans 3 years, with the latest figure at $0.45 for Q2 2021.

  • For Q2 2021, Debt to Equity fell 3.16% year-over-year to $0.45; the TTM value through Jun 2021 reached $0.45, down 3.16%, while the annual FY2020 figure was $0.88, 52.48% down from the prior year.
  • Debt to Equity reached $0.45 in Q2 2021 per VYNE's latest filing, up from $0.36 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $1.86 in Q4 2019 to a low of $0.36 in Q1 2021.
  • Average Debt to Equity over 3 years is $0.78, with a median of $0.67 recorded in 2020.
  • The largest YoY upside for Debt to Equity was 3.16% in 2021 against a maximum downside of 52.52% in 2021.
  • A 3-year view of Debt to Equity shows it stood at $1.86 in 2019, then plummeted by 52.48% to $0.88 in 2020, then tumbled by 49.63% to $0.45 in 2021.
  • Per Business Quant, the three most recent readings for VYNE's Debt to Equity are $0.45 (Q2 2021), $0.36 (Q1 2021), and $0.88 (Q4 2020).